Results of the FUTURE trial did not demonstrate an advantage for the use of fractional flow reserve compared with coronary angiography alone in making treatment decisions for patients with multivessel coronary artery disease, according to findings presented Saturday at the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany.